Fujikawa Keita | First Department Of Internal Medicine Nagasaki University Hospital Of Medicine And Dentistry Graduat

スポンサーリンク

概要

関連著者

もっと見る

著作論文

Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population
A significantly impaired natural killer cell activity due to a low activity on a per-cell basis in rheumatoid arthritis
Cutaneous vasculitis induced by TNF inhibitors : a report of three cases
Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics
Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables
Successful treatment of chronic lupus myocarditis with prednisolone and mizoribine
Long-term efficacy of intravenously administered immunoglobulin in a case of polymyositis with limited application of steroid therapy.
Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor
In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline
Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab : comparison with the remission by the clinical disease activity index
Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows and excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors

もっと見る

スポンサーリンク